NZ577442A - Arylsulfonamide compounds - Google Patents

Arylsulfonamide compounds

Info

Publication number
NZ577442A
NZ577442A NZ577442A NZ57744207A NZ577442A NZ 577442 A NZ577442 A NZ 577442A NZ 577442 A NZ577442 A NZ 577442A NZ 57744207 A NZ57744207 A NZ 57744207A NZ 577442 A NZ577442 A NZ 577442A
Authority
NZ
New Zealand
Prior art keywords
compound
raryl
compound according
alkyl
rheteroaryl
Prior art date
Application number
NZ577442A
Other languages
English (en)
Inventor
Jonathan Bayldon Baell
Guillaume Laurent Lessene
Brad Edmund Sleebs
Wayne J Fairbrother
John A Flygare
Michael F Koehler
Original Assignee
Genentech Inc
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Inst Medical W & E Hall filed Critical Genentech Inc
Publication of NZ577442A publication Critical patent/NZ577442A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NZ577442A 2006-11-15 2007-11-15 Arylsulfonamide compounds NZ577442A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85931506P 2006-11-15 2006-11-15
PCT/US2007/084873 WO2008061208A2 (en) 2006-11-15 2007-11-15 Arylsulfonamide compounds

Publications (1)

Publication Number Publication Date
NZ577442A true NZ577442A (en) 2012-02-24

Family

ID=39276199

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ577442A NZ577442A (en) 2006-11-15 2007-11-15 Arylsulfonamide compounds

Country Status (9)

Country Link
US (1) US8168645B2 (OSRAM)
EP (1) EP2094672B1 (OSRAM)
JP (1) JP5366817B2 (OSRAM)
CN (1) CN101535280B (OSRAM)
AU (1) AU2007319209B2 (OSRAM)
CA (1) CA2666837C (OSRAM)
ES (1) ES2423029T3 (OSRAM)
NZ (1) NZ577442A (OSRAM)
WO (1) WO2008061208A2 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
WO2009097578A1 (en) 2008-02-01 2009-08-06 Takeda Pharmaceutical Company Limited Oxim derivatives as hsp90 inhibitors
WO2009143246A2 (en) * 2008-05-21 2009-11-26 Genentech, Inc. Arylsulfonamide compounds, compositions and methods of use
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
EA020586B1 (ru) 2009-09-10 2014-12-30 Новартис Аг СУЛЬФОНАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ СЕМЕЙСТВА Bcl-2, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ РАКА
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
US20140335074A1 (en) 2011-12-13 2014-11-13 Buck Institute For Research On Aging Methods for improving medical therapies
EA201491268A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
JP2015503518A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
EP3669881B1 (en) 2014-01-28 2022-03-30 Buck Institute for Research on Aging Compositions for use in the treatment of senescence-assiocated eye disease and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
SG11202005785XA (en) 2018-01-10 2020-07-29 Recurium Ip Holdings Llc Benzamide compounds
CN108276395B (zh) * 2018-02-09 2021-02-26 合肥华方医药科技有限公司 一种多沙唑嗪杂质的制备方法
CN108570039B (zh) * 2018-04-25 2022-09-23 上海美迪西生物医药股份有限公司 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
CN109851535A (zh) * 2019-01-30 2019-06-07 天津现代职业技术学院 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法
CN113248415B (zh) * 2021-05-26 2022-08-09 苏州正永生物医药有限公司 一种abt-737关键中间体的制备方法以及abt-737的制备方法
FI4426434T3 (fi) 2021-11-02 2025-11-24 Flare Therapeutics Inc Pparg:n käänteisagonisteja ja niiden käyttöjä

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2003080586A1 (en) * 2002-03-21 2003-10-02 Abbott Laboratories N-sulfonylurea apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
EP1686121B1 (en) 2003-11-20 2010-02-10 Mitsubishi Gas Chemical Company, Inc. Liquid cyclohexane-tricarboxylic acid anhydride
JP5284641B2 (ja) * 2004-05-26 2013-09-11 アボット・ラボラトリーズ Ｎ−スルホニルカルボキシイミドアミドアポトーシス促進剤
KR20070046180A (ko) 2004-08-20 2007-05-02 더 리젠츠 오브 더 유니버시티 오브 미시간 항세포사멸 ｂｃｌ-2군 구성원의 소분자 억제제 및 이의용도
US8101619B2 (en) 2004-12-08 2012-01-24 Solvay Pharmaceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
NZ561609A (en) 2005-05-12 2010-03-26 Abbott Lab 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters

Also Published As

Publication number Publication date
JP5366817B2 (ja) 2013-12-11
CA2666837C (en) 2015-01-13
CN101535280A (zh) 2009-09-16
HK1134283A1 (en) 2010-04-23
AU2007319209A1 (en) 2008-05-22
CA2666837A1 (en) 2008-05-22
US20100056517A1 (en) 2010-03-04
JP2010510237A (ja) 2010-04-02
WO2008061208A2 (en) 2008-05-22
US8168645B2 (en) 2012-05-01
ES2423029T3 (es) 2013-09-17
EP2094672B1 (en) 2013-05-29
EP2094672A2 (en) 2009-09-02
CN101535280B (zh) 2012-06-27
AU2007319209B2 (en) 2012-04-19
WO2008061208A3 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
CA2666837C (en) Arylsulfonamide compounds
ES2967983T3 (es) Compuestos
WO2017101803A1 (zh) 一种新型egfr和alk激酶的双重抑制剂
US20100197711A1 (en) Benzothiazole compounds
US20090030197A1 (en) Quinoline Intermediates of Receptor Tyrosine Kinase Inhibitors and the Synthesis Thereof
US10421743B2 (en) Tetrahydroisoquinolines as PRMT5 inhibitors
AU2019218187B2 (en) Dioxinoquinoline compounds, preparation method and uses thereof
AU2013300344A1 (en) N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer
Altıntop et al. Synthesis and evaluation of a series of 1, 3, 4-thiadiazole derivatives as potential anticancer agents
CA2871453A1 (en) Quinazolinedione derivative
JP7190755B2 (ja) オキサジノキナゾリンおよびオキサジノキノリン系化合物、ならびに調製方法およびその使用
JP5227179B2 (ja) ３，６−ジヒドロ−２−オキソ−６ｈ−１，３，４−チアジアジン誘導体
US20090264427A1 (en) 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors
CN111440177B (zh) 一种取代吡唑并[1,5-a]嘧啶类化合物及其制备方法和应用
ES2328929T3 (es) Dihidroquinazolinas 2-sustituidas.
JP7022454B2 (ja) ジオキシノキノリン系化合物、その調製方法および使用
HK1134283B (en) Arylsulfonamide compounds
Brzozowski et al. Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1, 4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII
AU2024290917A1 (en) Polo-like kinase 1 inhibitors
CN117486813A (zh) N-二取代苯基丙烯酰胺类化合物及其药物组合物和用途
HK40042713A (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 NOV 2017 BY THOMSON REUTERS

Effective date: 20140912

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2018 BY THOMSON REUTERS

Effective date: 20171012

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2019 BY THOMSON REUTERS

Effective date: 20181018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2020 BY THOMSON REUTERS

Effective date: 20191017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2021 BY THOMSON REUTERS

Effective date: 20200926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2022 BY THOMSON REUTERS

Effective date: 20211002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2023 BY THOMSON REUTERS

Effective date: 20221003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2024 BY ANAQUA SERVICES

Effective date: 20231020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2025 BY ANAQUA SERVICES

Effective date: 20241022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 NOV 2026 BY ANAQUA SERVICES

Effective date: 20251022